title: Inhibition of cell migration by PITENINs: the role of ARF6.
abstract: We have reported previously the development of small-molecule phosphatidylinositol-3,4,5-trisphosphate (PIP3) antagonists (PITs) that block pleckstrin homology (PH) domain interaction, including activation of Akt, and show anti-tumor potential. Here we show that the same molecules inhibit growth factor-induced actin remodeling, lamellipodia formation and, ultimately, cell migration and invasion, consistent with an important role of PIP3 in these processes. In vivo, a PIT-1 analog displays significant inhibition on tumor angiogenesis and metastasis. ADP ribosylation factor 6 (ARF6) was recently identified as an important mediator of cytoskeleton and cell motility, which is regulated by PIP3-dependent membrane translocation of the guanine nucleotide exchange factors (GEFs), such as ADP-ribosylation factor nucleotide binding site opener (ARNO) and general receptor for 3-phosphoinositides (GRP1). We demonstrate that PITs inhibit PIP3/ARNO or GRP1 PH domain binding and membrane localization, resulting in the inhibition of ARF6 activation. Importantly, we show that expression of the constitutively active mutant of ARF6 attenuates inhibition of lamellipodia formation and cell migration by PITs, confirming that inhibition of ARF6 contributes to inhibition of these processes by PITs. Overall, our studies demonstrate the feasibility of developing specific small-molecule targeting PIP3 binding by PH domains as potential anticancer agents that can simultaneously interfere with cancer development at multiple points.
authors.affiliation: Department of Biochemistry, Tufts University School of Medicine, Boston, MA 02111, USA.
authors.forename: B
authors.initials: B
authors.lastname: Miao
authors.forename: I
authors.initials: I
authors.lastname: Skidan
authors.forename: J
authors.initials: J
authors.lastname: Yang
authors.forename: Z
authors.initials: Z
authors.lastname: You
authors.forename: X
authors.initials: X
authors.lastname: Fu
authors.forename: M
authors.initials: M
authors.lastname: Famulok
authors.forename: B
authors.initials: B
authors.lastname: Schaffhausen
authors.forename: V
authors.initials: V
authors.lastname: Torchilin
authors.forename: J
authors.initials: J
authors.lastname: Yuan
authors.forename: A
authors.initials: A
authors.lastname: Degterev
mesh_terms: D000089982:ADP-Ribosylation Factor 6; D020727:ADP-Ribosylation Factors / Q000502:physiology*; D000199:Actins / Q000378:metabolism; D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D001943:Breast Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement; D003599:Cytoskeleton / Q000187:drug effects / Q000378:metabolism; D005260:Female; D006801:Humans; D008175:Lung Neoplasms / Q000556:secondary; D008297:Male; D008546:Melanoma, Experimental / Q000556:secondary; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000473:pathology*; D009389:Neovascularization, Pathologic / Q000473:pathology; D018129:Phosphatidylinositol Phosphates / Q000037:antagonists & inhibitors; D051381:Rats; D017207:Rats, Sprague-Dawley; D012878:Skin Neoplasms / Q000473:pathology
chemical_list: D000089982:ADP-Ribosylation Factor 6; D000199:Actins; D020533:Angiogenesis Inhibitors; D018129:Phosphatidylinositol Phosphates; C060974:phosphatidylinositol 3,4,5-triphosphate; D020727:ADP-Ribosylation Factors; C000715348:ARF6 protein, human; C000715727:Arf6 protein, mouse; C000715349:Arf6 protein, rat